Nutshell Therapeutics divulges new TP53 Y220C reactivators
May 6, 2025
Nutshell Therapeutics Inc. has synthesized deuterated indolizine compounds acting as cellular tumor antigen p53 (TP53) (Y220C mutant) reactivators reported to be useful for the treatment of cancer.